Study of STP938 Dencatistat Tablets for Adults with Relapsed or Refractory B-Cell and T-Cell Lymphomas Phase 1 Dose Finding and Phase 2 Treatment Effectiveness Evaluation

What this Trial Is About

Researchers are evaluating the drug STP938, an inhibitor of the enzyme CTPS1, in adults with relapsed or refractory B-cell and T-cell lymphomas. This study aims to determine the safety, tolerability, best dose, and preliminary effectiveness of STP938 in treating these lymphomas. The study includes two parts a Phase 1 dose escalation and a Phase 2 cohort expansion. STP938 is given orally as a tablet. In Phase 1, participants receive increasing doses of STP938 to find the best dose that can be safely administered. In Phase 2, the drug is given at the determined dose to different groups of patients with various types of B and T cell lymphomas. Blood samples are collected throughout the study to assess the drugs effects on lymphoma and the body. Participants will be monitored for safety, drug absorption, and treatment response for about nine months. Assessments include measuring drug levels in the blood and evaluating tumor response and progression using established lymphoma criteria. The study tracks how well participants tolerate the treatment and how their disease responds, with ongoing safety checks during the study period.

A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas